190 related articles for article (PubMed ID: 36190243)
1. Drug Degradation Caused by
Pi R; Chen X; Meng J; Liu Q; Chen Y; Bei C; Wang C; Gao Q
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0103422. PubMed ID: 36190243
[TBL] [Abstract][Full Text] [Related]
2. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
[TBL] [Abstract][Full Text] [Related]
3.
An H; Sun W; Liu X; Wang T; Qiao J; Liang J
Microbiol Spectr; 2023 Sep; 11(5):e0462722. PubMed ID: 37732805
[TBL] [Abstract][Full Text] [Related]
4. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
Yang M; Zhan S; Fu L; Wang Y; Zhang P; Deng G
Drug Discov Ther; 2022 May; 16(2):99-101. PubMed ID: 35418550
[TBL] [Abstract][Full Text] [Related]
5.
Shoen C; DeStefano M; Hafkin B; Cynamon M
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784848
[TBL] [Abstract][Full Text] [Related]
6. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
7. Novel oxazolidinones harbor potent
Wang C; Wang G; Huo F; Xue Y; Jia J; Dong L; Zhao L; Wang F; Huang H; Duan H
Front Med (Lausanne); 2022; 9():1067516. PubMed ID: 36523787
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
9. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report.
Guo W; Hu M; Xu N; Shangguan Y; Xia J; Hu W; Li X; Zhao Q; Xu K
Int J Antimicrob Agents; 2023 Aug; 62(2):106875. PubMed ID: 37276894
[TBL] [Abstract][Full Text] [Related]
10. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
11. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Zhang GX; Liu TT; Ren AX; Liang WX; Yin H; Cai Y
Infection; 2024 Jun; 52(3):787-800. PubMed ID: 38717734
[TBL] [Abstract][Full Text] [Related]
12.
McNeil MB; Dennison DD; Shelton CD; Parish T
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760892
[TBL] [Abstract][Full Text] [Related]
13.
Guo S; Wang B; Fu L; Chen X; Zhang W; Huang H; Lu Y
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0097421. PubMed ID: 34398674
[TBL] [Abstract][Full Text] [Related]
14. Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities.
Boshoff HIM; Young K; Ahn YM; Yadav VD; Crowley BM; Yang L; Su J; Oh S; Arora K; Andrews J; Manikkam M; Sutphin M; Smith AJ; Weiner DM; Piazza MK; Fleegle JD; Gomez F; Dayao EK; Prideaux B; Zimmerman M; Kaya F; Sarathy J; Tan VY; Via LE; Tschirret-Guth R; Lenaerts AJ; Robertson GT; Dartois V; Olsen DB; Barry CE
ACS Infect Dis; 2024 May; 10(5):1679-1695. PubMed ID: 38581700
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST
Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022
[TBL] [Abstract][Full Text] [Related]
16. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.
Beckert P; Hillemann D; Kohl TA; Kalinowski J; Richter E; Niemann S; Feuerriegel S
Antimicrob Agents Chemother; 2012 May; 56(5):2743-5. PubMed ID: 22371899
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China.
Yang C; Lei H; Wang D; Meng X; He J; Tong A; Zhu L; Jiang Y; Dong M
Jpn J Infect Dis; 2012; 65(3):240-2. PubMed ID: 22627306
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Huang TS; Liu YC; Sy CL; Chen YS; Tu HZ; Chen BC
Antimicrob Agents Chemother; 2008 Jun; 52(6):2226-7. PubMed ID: 18391030
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Wu X; Meng J; Yuan H; Zhong D; Yu J; Cao G; Liu X; Guo B; Chen Y; Li Y; Shi Y; Gordeev MF; Wu J; Zhang J
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0040921. PubMed ID: 34398672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
